explore -WSS

explore

author：knowledge 2025-08-28 06:24:37 - browse：571

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Elisabeth Bik tackles the widespread issue of research misconduct

WSS

Flint parents haunted by uncertainty, fears of lead poisoning

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

When waiting feels immoral: Empathy in the emergency department

Pharma showers House GOP doctor with campaign cash

Pharma showers House GOP doctor with campaign cash

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

explore

explore

focus

Anesthesiologist group: stop taking Ozempic before surgery

Pharma showers House GOP doctor with campaign cash

What does generative AI mean for health care? We asked experts

CDC panel: People 65 and older should get a Covid spring booster shot

Apple is now the first public company to be valued at $3 trillion

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Apple is now the first public company to be valued at $3 trillion

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Virginia high school admissions case could be legal follow

The a glaring gap in research on serious mental illness and primary care

focus

Late stage cancers on the rise after pandemic delayed screenings

Group behind ProMed defends move to subscription

H.R. 3 is the wrong path to lower drug costs

Physicians aren't 'burning out.' They're suffering from moral injury

Pfizer is about to make a big push in cancer. Will investors listen?

STAT Madness 2024: Meet the contenders

leisure time

focus

entertainment

focus